Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis

Schizophrenia Research

Volumn 134, Issue 1, 2012, Pages 16-19

  Garcia Rizo, Clemente ^a   Fernandez Egea, Emilio ^b,c   Oliveira, Cristina ^a   Justicia, Azucena ^b   Parellada, Eduard ^a,d,e   Bernardo, Miguel ^a,d,e   Kirkpatrick, Brian ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^f TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Drug na ve; First episode of psychosis; Prolactin; Schizophrenia

Indexed keywords

GHRELIN; HYDROCORTISONE; NEUROLEPTIC AGENT; PROLACTIN; THYROTROPIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BRIEF PSYCHOTIC DISORDER; CLINICAL ARTICLE; CONFOUNDING VARIABLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HORMONE ACTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NONAFFECTIVE PSYCHOSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEX DIFFERENCE; SMOKING; SOCIAL STATUS; THYROTROPIN BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; FEMALE; GHRELIN; HUMANS; HYDROCORTISONE; HYPERPROLACTINEMIA; MALE; PROLACTIN; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THYROTROPIN;

EID: 84155165370     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.07.025     Document Type: Article

References (25)

1. Aston J., Rechsteiner E., Bull N., Borgwardt S., Gschwandtner U., Riecher-Rossler A. Hyperprolactinaemia in early psychosis-Not only due to antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(7):1342-1344.
2. Duval F., Mokrani M.C., Monreal J., Bailey P., Valdebenito M., Crocq M.A., Macher J.P. Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. Psychoneuroendocrinology 2003, 28:627-642.
3. Engler H., Doenlen R., Riether C., Engler A., Niemi M.B., Besedovsky H.O., del Rey A., Pacheco-Lopez G., Feldon J., Schedlowski M. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. Brain Behav. Immun. 2009, 23:518-526.
4. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
5. Fernandez-Egea E., Bernardo M., Heaphy C.M., Griffith J.K., Parellada E., Esmatjes E., Conget I., Nguyen L., George V., Stoppler H., Kirkpatrick B. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr. Bull. 2009, 35:437-442.
6. Fernandez-Egea E., Miller B., Garcia-Rizo C., Bernardo M., Kirkpatrick B. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J. Clin. Psychopharmacol. 2011, 31:154-159.
7. First, M., Spitzer, R.L., 1999. SCID-I Structured Clinical Interview for the DSM-IV Axis I Disorders [Spanish] (trans. J Blanch, I Andreu). Masson.
8. Friedrich N., Schneider H.J., Spielhagen C., Markus M.R., Haring R., Grabe H.J., Buchfelder M., Wallaschofski H., Nauck M. The association of serum prolactin concentration with inflammatory biomarkers - Cross-sectional findings from the population-based study of health in Pomerania. Clin. Endocrinol. (Oxf.) 2011, (Apr 15, Electronic publication ahead of print). doi:10.1111/j.1365-2265.2011.04075.x.
9. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
10. Harvey A.T., Flockhart D., Gorski J.C., Greenblatt D.J., Burke M., Werder S., Preskorn S.H. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. J. Clin. Pharmacol. 2004, 44:1173-1184.
11. Jaroenporn S., Nagaoka K., Kasahara C., Ohta R., Watanabe G., Taya K. Physiological roles of prolactin in the adrenocortical response to acute restraint stress. Endocr. J. 2007, 54:703-711.
12. Kapur S., Langlois X., Vinken P., Megens A.A., De Coster R., Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 2002, 302:1129-1134.
13. Lee B.H., Kim Y.K. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:658-662.
14. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
15. Mackin P., Waton A., Nulkar A., Watkinson H.M. Prolactin and smoking status in antipsychotic-treated patients. J. Psychopharmacol. 2011, 25(5):698-703.
16. Messini C.I., Dafopoulos K., Chalvatzas N., Georgoulias P., Anifandis G., Messinis I.E. Effect of ghrelin and thyrotropin-releasing hormone on prolactin secretion in normal women. Horm. Metab. Res. 2010, 42:204-208.
17. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, [Jun 3, Electronic publication ahead of print]. doi:10.1111/j.1365-2265.2011.04075.x.
18. Onaka T., Takayanagi Y., Leng G. Metabolic and stress-related roles of prolactin-releasing peptide. Trends Endocrinol. Metab. 2010, 21:287-293.
19. Oride A., Kanasaki H., Purwana I.N., Miyazaki K. Possible involvement of mitogen-activated protein kinase phosphatase-1 (MKP-1) in thyrotropin-releasing hormone (TRH)-induced prolactin gene expression. Biochem. Biophys. Res. Commun. 2009, 382:663-667.
20. Peralta V., Cuesta M.J. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994, 53:31-40.
21. Rosenberg S.D., Drake R.E., Wolford G.L., Mueser K.T., Oxman T.E., Vidaver R.M., Carrieri K.L., Luckoor R. Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. Am. J. Psychiatry 1998, 155:232-238.
22. Sarro S., Duenas R.M., Ramirez N., Arranz B., Martinez R., Sanchez J.M., Gonzalez J.M., Salo L., Miralles L., San L. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. Schizophr. Res. 2004, 68:349-356.
23. Segal M., Avital A., Berstein S., Derevenski A., Sandbank S., Weizman A. Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:378-382.
24. Stubbs B. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density. J. Psychiatr. Ment. Health Nurs. 2009, 16:838-842.
25. Zhang-Wong J.H., Seeman M.V. Antipsychotic drugs, menstrual regularity and osteoporosis risk. Arch. Womens Ment. Health 2002, 5:93-98.